Adempas\u00ae is the commercial brand name of Riociguat Tablets, an orally active soluble guanylate cyclase stimulator developed by Bayer. It stimulates soluble guanylate cyclase to elevate intracellular cGMP concentration, dilate pulmonary vasculature and reduce pulmonary arterial pressure.<\/p>\n\n\n\n
Main Indications<\/strong> Common Side Effects<\/strong> Approval Status in China<\/strong> Buy Adempas (Riociguat Tablets)\u00a0online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.<\/p>\n\n\n\n <\/p>\n","protected":false},"excerpt":{"rendered":" Adempas\u00ae is the commercial brand name of Riociguat Tablets, an orally active soluble guanylate cyclase stimulator developed by Bayer. It stimulates soluble guanylate cyclase to elevate intracellular cGMP concentration, dilate pulmonary vasculature and reduce pulmonary arterial pressure. Main IndicationsTreatment of adult patients with pulmonary arterial hypertension (PAH, WHO functional class II\u2013III) to improve exercise capacity;Treatment […]<\/p>\n","protected":false},"author":4,"featured_media":3495,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[101],"tags":[],"class_list":["post-3494","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-drug-news"],"blocksy_meta":[],"yoast_head":"\n
Treatment of adult patients with pulmonary arterial hypertension (PAH, WHO functional class II\u2013III) to improve exercise capacity;
Treatment of chronic thromboembolic pulmonary hypertension (CTEPH) after surgical intervention or for inoperable cases to boost patients\u2019 exercise tolerance.<\/p>\n\n\n\n
Common mild adverse reactions: Headache, facial flushing, dizziness, dyspepsia and peripheral edema.
Laboratory abnormalities: Rare mild hemoglobin reduction.
Severe but manageable risks: Severe symptomatic hypotension, gastrointestinal hemorrhage and hypersensitivity reactions.<\/p>\n\n\n\n
Adempas\u00ae (Riociguat Tablets, 1mg, domestic Chinese brand name: Anji\u2019ao) was officially approved for marketing in China in 2017. It is currently a prescription drug included in China\u2019s Category B medical insurance.<\/p>\n\n\n\n